Figure 1.
Development of leukemia in mice with targeted Phf6 deletion. (A) Kaplan-Meier survival curve showing deaths due to hematopoietic neoplasm in Phf6+/− mice vs Phf6+/+ control mice. Note, a proportion (42% in the female cohort described here) of aged wild-type C57BL/6 mice develop spontaneous hematopoietic neoplasms. A vertical dash on the survival curve indicates deaths due to other causes. Data were analyzed using the Gehan–Breslow–Wilcoxon test. (B) Representative disease-free wild-type control spleen and spleens from Phf6+/+ control mice and Phf6+/− mice with hematopoietic malignancy. (C) Spleen weight of Phf6+/− mice (n = 10) compared with sick Phf6+/+ mice (n = 9), both with hematopoietic malignancy. Data were analyzed using the 2-tailed Student t test and are displayed as individual data points with mean ± standard error of the mean (SEM). (D) Table showing immunophenotype of Phf6+/− and control tumors. There was no significant effect of Phf6 heterozygous mutation. Data were analyzed using the χ2 test. (E) Outcome of transplantation of malignant splenocytes from Phf6+/− and Phf6+/+ mice and photographs of spleens from Rag1−/− recipient mice. Scale bars, 1 cm.